Agave syrup extract having anticancer activity

ABSTRACT

The present invention comprises an  agave  extract stored for at least eight weeks, having phytochemicals preferably selected from the group comprising flavonoids, polycosanols and sapogenins, that inhibit cancer cell growth over cells of breast and lymphoma and which provides the  agave  extract with antioxidant and chemopreventive properties.

BACKGROUND OF THE INVENTION

A. Field of the Invention

The present invention is related to processes or methods to obtainextracts from agave syrup containing various phytochemicals such aspolyphenols, flavonoids, saponins, phytosterols, steroids, triterpens,polycosanols and other natural products having proved antioxidantproperties and more particularly to a method for using an agave syrupextract as an antioxidant, food supplement or as an anti-neoplasic,anti-carcinogenic or anti-tumoral preparation for the prevention orinhibition of growing cancers or the growth of cancer cells, such astumors or hormone-dependent or independent cancerigen cells, from breastand lymphoma.

B Description of Related Art

According to anthropologists, Mexico is the original source of the agaveplant (Agave spp). Said plant has been used since remote times as a foodsource, forage, medicine, as a fiber source (henequen, wild lettuce) andas a building material among other uses. In Mesoamerica humans havealways considered the importance of this plant since at least 9000years.

Indigenous people gradually selected the sweetest agaves since theycooked the plants inside earth holes having a bed of basalt rocks andstored them for future use. Mexican indigenous civilizations described14 different kinds of agave. The Mexoxochitli agave corresponds to theAmerican Agave species.

Some agaves were used for curing ataxia; other agaves were used toreestablish the health in women, especially after delivery and fortreating articulation pains. Agave leaves were also used for preventingscorbute and for the healing of injuries. Its main use was for theelaboration of alcoholic beverages such as pulque, mezcal, bacanora andtequila, which is produced from the Agave tequilana plant.

Taxonomically, the Agave genus pertains to the Agavaceae family. Thereare approximately 310 species of Agave known in the American Continent,from which 272 are found in Mexico, which led to consider Mexico as thecytogenetic origin of this important plant. The main characteristic ofthe Agave plant is its optimum adaptation to the arid conditions ofMesoamerica and Aridamerica. The plant pertains to the monocotiledoniagroup and to the lilacea order, which produce big and branched roots,succulent leaves having sunken stomas and has a photosyntheticmetabolism which allows the plant to adapt to low water conditions andto take advantage of the carbon dioxide more efficiently (GranadosSánchez 1994). The chromosomic number of the Americana Agave is 2n=60.

The aguamiel or the Agave sweet extract is considered as an importantbeverage since it has a good nutrimental value, supplies energy, and isrich in essential amino acids essential for human growth. The aguamielis a colorless, transparent liquid having a very sweet and pleasantflavor. It has a density of 1.049 g/cc and a total sugar content ofapproximately 10%. More of the 90% of the sugar content comprisessucrose (Granados Sánchez, 1994).

The vegetal material, aguamiel and syrup from the different agave kindshave been used since ancestral times for treating many maladies,specially for the prevention and treatment of diabetes, skin diseases asa scarring promoter, arthritis and cardiovascular diseases. However, thepossible substances and compounds involved in the above referredbiologic effects of the aguamiel are not very well known.

One of the possible action mechanisms may be related to the antioxidantactivity, which has not yet been measured for the aguamiel. It is onlyknown that the raw agave has an antioxidant capacity of 12.48 μmolstrolox equivalent (ET)/g and that such value is increased to 29.38 whenthe agave is boiled (Wu and collaborators, 2004).

There also exist several patents related to the fructooligosaccharides(FOS) or inulin extraction from the soluble dietetic fiber. Saidcompounds are considered to have prebiotic, anticholesterolemic andantidiabetic effects.

In addition to the inulin the sapogenins have been an extensivelyresearched agave compound family (Yang and col., 2006, Blunden and col.,1980, Blunden and col., 1986, Sharua and Khanna, 1980, Jin, Liu andYang, 2003). Jin, Zhang and Yang (2004), found three new steroidalsaponins (agamenosides H-J) and a new agavegenin together with six knownsteroids present in the residue coming from the separation of the fibersof the A. American leaves which are used in the fiber industry in China.

The steroidal saponins present in the Agave have shown to haveanti-inflammatory properties which can potentially help to preventand/or treat cancer. Da Silva and collaborators (2002) demonstrated theanti-inflammatory properties of a steroidal saponin extracted from Agaveattenuate. Said steroidal saponin didn't shown the hemolytic activityshown by other saponins due to the greater affinity of the steroids forcholesterol at the erythrocytes membrane. The saponins from Dracaenasurculosa, which is a plant from the Agavaceae family have been testedin vitro in order to determine its activity in leukemia promyelocytichuman cells (HL-60) and only three out of 9 saponins shown a slightlycytotoxic activity (Yokosuka, Mimaki y Sashida, 2000).

Additionally, there has been reported the presence of flavonoids in theagave. The agamennone was the first flavonoid reported in the agave(Parmar and col., 1992). Subsequently, there have been found other threerelated flavonoids (Tinto and col. 2005). However, it hasn't been provedany biologic activity by said compounds neither its anticancerigenactivity. Until now, all the reported activity related to agave syrupshas been attributed to the inulin or to the sapogenins.

Japanese patent JP 11049687 claims a cutaneous preparation made ofextracts from different Agave plants for external use, which stimulatesthe retention of water and inhibit the melamine production and thus, itis useful for dermatitis, to prevent oily skin, acne and dandruff. TheAloe Vera juice has been claimed for the treatment of mastitis indomestic cattle and for many useful common use products such asshampoos, creams for the skin, etc.

Mexican patent application of Meixueiro Valverde PCT/MX2004/0000417disclose the production of an Agave liquid extract having anticancerigenand antiviral properties (virus sincitial of the subgroup of theMoxovirus) and that may be used as a cellular and glandularreconstituent in humans as well as in domestic animals. The extract canbe used for treating asthma, sinusitis, tonsillitis, mycotic infectionsand intestinal parasites. The inventor relates the positive effects tophytochemical compounds having a proteinic nature which are obtainedfrom the agavacea plant fleshy leaf cuticle and salvia. The method forthe obtention of the extract comprises harvesting the agave fleshy leafshaving from 4 to 15 years old; boiling the fleshy leafs for a time offrom 20 to 180 minutes in water at a temperature of from 70 to 100° C.(with a water-fleshy leafs relation of 2 to 4:1); grinding the boiledfleshy leafs and filtering the resulting liquid. The extract itselfcomprises the viscous greyish green filtered matter having a solidcontent of 5%. The raw extracts from two tested agaves (alone andcombined) had a good anticancerigen activity in vitro. However theinventor didn't carry out any kind of analysis in order to find whichphytochemical compounds may have anticancerigen and antiviral potential.Furthermore, the related art does not disclose the anticancerigenactivity of the agave syrup which was found by the applicant.

The use of the agave syrup extracts provides a source of activeingredients—not used until now—, which can be prepared and administeredin a suitable way in many ways, including the treatment of cancer.

Applicant discovered that several kinds of phytochemicals from agavesyrup or its extracts have potential synergic effects such as inhibitingcancer cells and or providing antioxidant effects.

Therefore, applicant developed an agave syrup extract composition (Agavespp) from several Agave varieties such as A. atrovirens, A salmiana, A.lehmanni and a related method comprising the use of its components aloneor combined with other known and effective nutraceutic compounds such asvitamins A, C, and E, and/or sources of selenium for inhibiting thegrowth of cancer cells and/or providing an antioxidant effect.

The agave syrup extract composition of the present invention inhibitsthe growth of cancer cells and has antioxidant effects, for example, asan active ingredient in a food supplement and/or foods, cosmetics ormedicines, or it may be an active ingredient in antineoplastic,anticancerigen or anti-tumoral preparations, for treating as well aspreventing cancer or inhibiting the growth of cancer cells, such ashormone dependent or independent tumors such as breast, prostate, colonor liver cancer.

The agave syrup extract composition of the present invention comprisespartially purified extracts derived from agave syrup which containsaponins, phytosterols, total phenolic compounds such as polyphenols,flavonoids and tannins which have a high antioxidant activity. Saidextracts may be partially or totally purified by chromatography and/orother physic and/or chemical and/or bioseparation methods and befractionated by a fast centrifugal partition chromatography.

The extracts may be mixed with two or more carriers, excipients and/ordiluents pharmaceutically or veterinary acceptable.

The invention further comprises the isolated or purified compoundsobtained from agave syrup. Said compounds are useful in an isolated wayor combined at several concentrations. The compounds may besynthetically obtained as well as by its modification by severalchemical and/or enzymatic processes.

SUMMARY OF THE INVENTION

It is therefore a main object of the present invention to provide anagave syrup extract composition (Agave spp) from several Agave varietiessuch as A. atrovirens, A salmiana, A. lehmanni useful for inhibiting thegrowth of cancer cells and/or providing an antioxidant effect.

It is an additional object of the present invention to provide a methodcomprising the use of components and combinations of an agave syrupextract composition (Agave spp) from several Agave varieties such as A.atrovirens, A salmiana, A. lehmanni alone or combined with other knownand effective nutraceutical compounds such as vitamins A, C, and E,and/or sources of selenium for inhibiting the growth of cancer cellsand/or providing an antioxidant effect.

It is yet a main object of the present invention, to provide an agavesyrup extract composition of the above referred nature which may be usedas an active ingredient in a food supplement and/or foods, cosmetics ormedicines, or it may be an active ingredient in antineoplastic,anticancerigen or anti-tumoral preparations, for treating as well aspreventing cancer or inhibiting the growth of cancer cells, such ashormone dependent or independent tumors such as breast, prostate, colonor liver cancer.

It is still a main object of the present invention, to provide an agavesyrup extract composition of the above referred nature, which comprisespartially purified extracts derived from agave syrup which containsaponins, phytosterols, total phenolic compounds such as polyphenols,flavonoids and tannins which have a high antioxidant activity. Saidextracts may be partially or totally purified by chromatography and/orother physic and/or chemical and/or bioseparation methods and befractionated by a fast centrifugal partition chromatography.

It is another main object of the present invention to provide an agavesyrup extract composition of the above referred nature which may bemixed with two or more carriers, excipients and/or diluentspharmaceutically or veterinary acceptable.

These and other objects and advantages of the present invention willbecome apparent to those persons having an ordinary skill in the art,from the following detailed description of the invention which will bemade with reference to the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 comprises a graphic showing a comparison between the cytoxicityexerted over three cellular lines of human cancer from extracts obtainedwith methanol, acetone or ethanol at an 80% in water from agave syrupstored for more than three months.

FIG. 2 comprises a graphic that show the effect of the storing period atambient temperature in three samples of agave syrup coming fromdifferent places over the anticancerigen activity in hormone dependentbreast cancer cells (MCF7) considering the viability percentagedecrease.

FIG. 3 comprises a graphic showing the effect of the storing periodeffect at ambient temperature in three samples of agave syrup comingfrom different places over the anticancerigen activity in colon cancercells (Caco2) considering the viability percentage decrease.

FIG. 4 comprises a graphic showing the effect of the storing periodeffect at ambient temperature in three samples of agave syrup comingfrom different places over the anticancerigen activity in liver cancercells (HepG2) considering the viability percentage decrease.

FIG. 5 comprises a graphic showing the result of the screening ofcompounds having anticancerigen activity obtained from an agave syrupextract obtained by 80% methanol and separated by means of a fastcentrifugal partition chromatography together with a solvent systemcomprised by water:ethyl acetate (92:2) and butanol:water:ethyl acetate(47:13:40).

FIG. 6 comprises a graphic showing the chromatogram obtained from theseparation of compounds by a fast centrifugal partition chromatographyof an 80% methanolic extract of 10 g of agave syrup together with asolvent system comprised by water:ethyl acetate (92:2) andbutanol:water:ethyl acetate (47:13:40).

FIG. 7 comprises a graphic showing the growing inhibition over coloncancer cells of the fractions having different partition coefficientobtained by CPC at normal mode with extrusion in a two phase systemcomprised by water:ethyl acetate (92:8) and butanol:water:ethyl acetate(47:13:40).

FIG. 8 comprises a graphic showing the chromatogram obtained by HPLC-MSof the fraction having the greater inhibitory effect of the experimentof FIG. 5.

FIG. 9 shows the chemical structure of agamenone (peak 3 of FIG. 7).

FIG. 10. comprises a graph showing the experimentally obtained uv_(max)value of agamenone.

FIG. 11 comprises a graph showing a screening for fractions withanti-lymphoma activity

FIG. 12 comprises a comparison of the main peaks observed in thechromatograms obtained at 280 nm for fractions with anti-lymphomaactivity.

FIG. 13 comprises a comparison chart showing the effect on cellviability of 18 samples from 9 different regions.

DETAILED DESCRIPTION OF THE INVENTION

Inventors discovered that the agave syrup activity increases in functionof the storing time of the processed product and that there areflavonoids, polycosanols and sapogenins present in said product whichare responsible for the anticancerigen activity.

The invention will be now described making reference to the followingexamples and the accompanying drawings.

The description and examples refer to the methods and steps for usingthe present invention concerning to the agave selection in terms ofconcentration and bioactivity of a given variety of agave in order toderivate the most useful use of the extracts and of the compoundspresent in any given variety for treating or preventing several kinds ofcancer as well as the various ways in which said extracts can beadministered in order to achieve the object of the present invention.Although the description and examples refer to certain Mexican agavevarieties used by the inventors in their research and conception of theinvention, it will be evident for persons skilled in the art that anyother agave variety will be included in the scope of the invention.

EXAMPLE 1

An agave syrup was obtained by boiling approximately 10 liters ofaguamiel during 5-6 hours until obtaining approximately 1 liter of syruphaving 70% of solids, which is stable at ambient conditions andresistant to microbial attacks. The aguamiel is extracted from agaveswhich are near florescence. The agave is cut (the floral tail isdestroyed and a cavity is formed in which the sap or aguamiel isdeposited). The cavity is covered with parts of the same maguey in orderto avoid animal attacks. Subsequently, the aguamiel is recollected byscratching the maguey in order to stimulate the production of sap.

EXAMPLE 2 Antioxidant Capacity and Anticancerigen Effect of Agave SyrupExtracts Stored for More Than Six Months at Ambient Temperature

In order to obtain an extract, 4 to 5 g of agave syrup produced inExample 1 stored for more than 6 months were mixed with 10 ml of 80%methanol. Subsequently the mix was centrifuged for 5 minutes at 1,000rpm. The supernatant antioxidant activity was evaluated by means of theORAC method giving a value of 61.87±4.02 μmols TROLOX equivalents/gsample. The anticancerigen activity in vitro was also evaluated usinghuman colon cancer cells cultivations (Caco-2), breast cancer cells(MCF-7), and liver cancer cells (HepG2). The growth inhibitionpercentage values were obtained using 15 mg/ml (syrup/cultivationmedia). It was observed that there was no significant effect over thegrowth of breast cancer cells. However, the growth of colon cancer cellswas inhibited by 84.89±0.29 and the growth of liver cells was inhibitedby 67.95±4.87.

EXAMPLE 3 Evaluation of the Effect of Solvent Over the Extraction ofAnticancerigen Compounds from Agave Syrup

As in Example 2, in order to obtain an extract, there were taken from 4to 5 g of agave syrup produced in Example 1 stored for more than 6months, which were mixed with 10 ml of methanol, acetone or ethanol atan 80% in water. Subsequently the mix was centrifuged and thesupernatant antioxidant activity over human cancer cellular linesdescribed in Example 2 was determined, FIG. 1 shows that methanol at an80% is the best solvent for the extraction of agave syrup compoundshaving anticancerigen activity. The acetone is the second best solventfor the extraction of agave syrup compounds and it was the only solventby which applicant was capable of obtaining supernatants havinginhibitory growth activity of breast cancer cells (MCF-7). With regardto the supernatants obtained by ethanol at an 80%, it was observedinhibitory growth activity of colon and liver cancer cells only.However, the observed activity of the extracts obtained by methanol wasless than half of the observed activity of the extracts obtained bymethanol.

EXAMPLE 4 Tested Agave Varieties and Determination of the OptimumStoring Time Before Extraction

In accordance with consumer subjective observations there was recognizedthe possibility that the agave syrup could have nutraceutical activity.Applicant considered of great importance to know about the effects thatthe storing time has over the breast, colon and liver cancer cell growthinhibitory activity. At the same time, there was evaluated the effectsof several agave plants coming from different places in order todetermine if the place of origin has any significance over the overalleffects of the plant.

There were tested 3 agave syrups obtained from different places, andtheir extracts were obtained by methanol at an 80% as described inExamples 2. FIG. 2 shows that breast cancer cells maintain a viabilitypercentage greater than 90% if there are used extracts from agave syrupstored by less than six months. However, viability percentages didn'tcome down from 80% even when there were used agave extracts stored forapproximately 4 months.

With regard to colon cancer, FIG. 3 comprises a graphic that shows thedecrease of the cellular viability with respect to the storing period ofthe used agave syrup. The graphic show that it is necessary to store theagave syrup for more than eight weeks in order to obtain significanteffects. The agave syrups obtained from three different places,decreased the cellular viability to approximately 50% after being storedfor approximately four months.

Additionally, the effect of the extracts over the liver cancer cellswhich are shown in FIG. 4 with respect to the storing period of theagave syrup, appears to be the same for the breast cancer cells.

Therefore, applicant deduced that the agave syrup must be stored for atleast 16 weeks in order to extract the active ingredients. Furthermore,it was evident that the compounds which have activity over the livercancer cells require more time to be modified by mechanisms intrinsic tothe product during the storing period.

EXAMPLE 5 Separation by Fast Centrifugal Partition Chromatography

In order to found the active compounds of the agave syrup, it wasperformed a fast centrifugal partition chromatography using a Kromatronequipment (France) using a 1 liter column. A mix of butanol:water:ethylacetate (47:13:40) was used as a stationary phase in order to extractmost of the sugars of the agave syrup using water:ethyl acetate (92:8)as a mobile phase. There was injected 5 g of syrup dissolved in 20 ml ofthe mobile phase. FIG. 5 shows that the obtained chromatogram at 260 nmhas a peak between the minute 20 to 25 which corresponds to the sugarsextracted from the agave syrup which are the main compounds of the agavesyrup. However the maximum activity peak can be found in the analysis ofthe last fractions showing the lipophilic characteristics of the productactive compounds. It must be emphasized that the fractions were testedat a concentration of 0.5 mg/ml (fraction/mammal cells cultivatingmedium).

The conditions of said experiment allowed to recollect only componentshaving partition coefficients (stationary/mobile phase concentration)lesser than or equal to 1 due to the utilization of a flow of 10 ml/minand a running time of 80 minutes, from which, the last 40 minutes werecarried out in extrusion mode.

This experiment revealed that the compounds which may possibly haveactivity were the least water soluble, since the activity increases inthe fractions obtained in the extrusion mode, i.e. when the compoundswere being extracted with the organic phase, Therefore, a secondexperiment was carried out with the same equipment but the flow and thequantity of agave syrup injected were raised in order to determine theprocess scalability and prove that the least water soluble compoundswere the active compounds.

FIG. 6 shows the chromatogram of the fast centrifugal partitionchromatography of 10 g of agave syrup diluted in 10 ml of the samemobile phase of the previous experiment. Once more, it was possible toseparate the compounds contained in the agave syrup in two principalfractions. Furthermore, it was proved that the compound separation byfast centrifugal partition chromatography was scalable. Even thoughthere was a rising in the quantity of agave syrup, the obtainedpartition coefficients were not affected in this experiment.

In order to carry out a bioassay of the fractions, there were selectedcolon cancer cells in order to observe the inhibitory action of saidfractions. FIG. 7 shows that the samples with the greatest partitioncoefficient were the samples that showed the greatest colon cancer cellinhibitory action.

EXAMPLE 6 Preliminary Identification of the Components in Agave SyrupActive Fraction with Colon Cancer Cell Inhibitory Action

In order to carry out a tentative identification of the activecomponents of the fraction obtained by CPC, it was analyzed by H PLC-MS.Using a column of C₁₈ (Zorbax 2.1×30 mm, 3.5 μm), the mobile phasecomprised methanol and water which was modified with 5 mM of ammoniumacetate at a flow of 0.5 ml/min. The column was balanced with 40% ofmethanol and a gradient was programmed in such way that, at a time of12.5 minutes, the methanol percentage was incremented to 90% andmaintained at said percentage during the last 5 minutes of theexperiment. The temperature at which the separation was carried out was40° C. and the chromatogram was obtained with positive ions between50-1500 m/z which were detected by the ion trap.

FIG. 8 shows the presence of 3 main peaks in one of the most activefractions. The molecular mass of said two compounds do not coincide withany of the reported in the different agave species, except for the thirdpeak. The third peak shown in FIG. 8 has a mass equal to the agamennone.FIG. 9 shows the agamennone structure or5,7-Dihydroxy-6,5′-dimethoxy-3′,4′-methylenedioxyflavanon whose reportedUV_(max) value match with the experimentally obtained value shown inFIG. 10. Furthermore, the spectrums of the other two present compoundscoincide with the spectrum of a flavonol or an isoflavone and itspositive ion masses are 304.3 and 332.3.

EXAMPLE 7 Screening for Bioactive Compounds by Fast CentrifugalPartition Chromatography

As in Example 2, an extract was obtained from 4 to 5 g of agave syrupproduced in Example 1 stored for at least 2 years, which were mixed with10 ml of acetone at an 80% in water. The extract was tested on lymphomacells (SU-DHL-4 and OCI-Ly7) and 50% inhibition was obtained at 5.5 and1.3 mg/ml.

To screen for possible bioactive compounds, fast centrifugal partitionchromatography was carried out in the same way as Example 5. FIG. 10shows that fractions with a partition coefficient near 1 presented thestrongest inhibition of lymphoma cell growth. The most bioactivefractions had a partition coefficient between 1.5 and 3.

EXAMPLE 8 Preliminary Identification of Compounds in Anti-LymphomaFractions

To carry out a preliminary characterization of components in the activefractions obtained from screening in Example 7, they were analyzed byHPLC-UV. Column used was C₁₈ (Zorbax Eclipse XDB-C18, 4.6×150 mm, 5 μm)with mobile phase of methanol and acidified water (0.1% formic acid) at0.5 ml/min, in gradient mode from 25% methanol and reaching 100% in 35minutes. Separation was carried out at 30° C. and data was recorded at280 nm as can be observed in FIG. 12. The four most active fractionscontained at least 14 different compounds which are shown in thefollowing table with their UV absorption spectra:

Retention time λmax 4.8 257, 289 6 229, 278, 309 7.5 228, 276, 305 10.5272 10.8 260, 310 11 298 11.8 265, 367 12.7 258, 296 12.9 216, 273 13.3225, 291 13.6 256, 295 13.9 218, 285, 274 14.3 292 14.7 290

EXAMPLE 9 Use of Agave Syrup as a Chemopreventive Aid

Extract produced in Example 7 was tested on hepatic cell line Hepa1c1c7for chemopreventive effect by evaluation of quinone reductase activity.Extract presented an effect from 0.2 to 4 mg/mL, and was cytotoxic athigher concentrations.

EXAMPLE 10 Validation of Activity of Extracts from Different AgaveSyrups

To evaluate that syrup from agaves produced in different regions ofMexico have similar levels of bioactivity, 18 samples from 9 states wereanalyzed. An extract was produced as in Example 7 for each of the agavesyrups. FIG. 13 shows that all syrups had a similar effect in cellularviability.

Finally it must be understood that the agave syrup extract havinganticancerigen activity of the present invention, is not limitedexclusively to the embodiments above described and illustrated and thatthe persons having ordinary skill in the art can, with the teachingprovided by the invention, make modifications to the agave syrup extracthaving anticancerigen activity of present invention, which will clearlybe within of the true inventive concept and of the scope of theinvention which is claimed in the following claims.

1. An agave extract comprising flavonoids, polycosanols and sapogeninsthat inhibit cancer cell growth over cells of breast and lymphoma andwhich provides the agave extract with antioxidant and chemopreventiveproperties, wherein said agave extract has been extracted as asupernatant from an agave syrup which has been stored for at least eightweeks when the agave syrup is mixed with water and a substance selectedfrom the group consisting of: methanol at a concentration of 80%,acetone at a concentration of 80% and ethanol at a concentration of 80%in order to promote an increase in bioactivity of said phytochemicals.2. The agave extract in accordance with claim 1, wherein the agaveextract is extracted by: mixing said agave syrup with water and asubstance selected from the group consisting of: methanol at aconcentration of 80%, acetone at a concentration of 80% and ethanol at aconcentration of 80%; and collecting supernatant extract, wherein saidextract has an inhibitory cancer cell growth activity over colon andliver cancer cells.
 3. The agave extract in accordance with claim 1,wherein the agave extract is extracted from an agave syrup which hasbeen stored for at least eight weeks by: mixing said agave syrup withwater and acetone at a concentration of 80% and collecting supernatantextract, wherein said extract has an inhibitory cancer cell growthactivity over colon and liver cancer cells.
 4. A method for inhibitinggrowth of cancer cells, wherein the cancer cells are breast and lymphomacancer cells, comprising administering to said cancer cells an agavesyrup extract having phytochemicals preferably selected from the groupcomprising flavonoids, polycosanols and sapogenins.
 5. The method forinhibiting growth of cancer cells in accordance with claim 4, whereinthe agave syrup extract is extracted from an agave syrup which has beenstored for at least eight weeks.
 6. The method for inhibiting growth ofcancer cells in accordance with claim 4, wherein the agave syrup extractis extracted from an agave syrup which has been stored for at leasteight weeks by mixing said agave syrup with water and a substanceselected from the group comprising: methanol at a concentration of 80%,acetone at a concentration of 80% and ethanol at a concentration of 80%;and collecting supernatant extract.
 7. The method for inhibiting thegrowth of cancer cells in accordance with claim 4, wherein the agavesyrup extract is extracted from an agave syrup which has been stored forat least eight weeks by mixing said agave syrup with water and acetoneat a concentration of 80%; and collecting supernatant extract whereinsaid extract has an inhibitory cancer cell growth activity, over breastand lymphoma cancer cells.